Terumo Co. (OTCMKTS:TRUMY) Short Interest Update

Terumo Co. (OTCMKTS:TRUMYGet Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 145,600 shares, a growth of 332.0% from the April 15th total of 33,700 shares. Based on an average daily volume of 200,600 shares, the short-interest ratio is currently 0.7 days.

Shares of OTCMKTS:TRUMY opened at $28.70 on Thursday. Terumo has a 1 year low of $28.15 and a 1 year high of $50.53. The business has a fifty day simple moving average of $30.61 and a 200 day simple moving average of $36.43. The firm has a market cap of $21.80 billion, a price-to-earnings ratio of 24.32 and a beta of 0.36.

Several analysts recently issued reports on TRUMY shares. Zacks Investment Research upgraded Terumo from a “sell” rating to a “hold” rating in a report on Wednesday, April 13th. JPMorgan Chase & Co. started coverage on Terumo in a report on Wednesday, January 26th. They set an “overweight” rating for the company.

About Terumo (Get Rating)

Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. The company operates through three segments: Cardiac and Vascular Company, General Hospital Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stent, intravascular ultrasound systems, imaging catheters, and others; coils and stents for treating cerebral aneurysm, aspiration catheters and clot retrievers for treating ischemic stroke, and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts.

Read More

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.